Business
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
(TheNewswire)   Toronto, Ontario – TheNewswire - 13 May, 2026 – Helix ...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy\n(TheNewswire)\n\n\n\n \n\n\nToronto, Ontario – TheNewswire\n- 13 May, 2026 – Helix BioPharma Corp. (TSX:\n“HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”)\n(“Helix” or the “Company”), a clinical-stage oncology\ncompany shaping a near future where today’s hard-to-treat cancers\nare vincible, is pleased to announce the following appointments,\neffective immediately: Zachary T. Stadnyk, former TSX Life Sciences\nLead and a biotech capital markets executive, has been appointed to\nthe Company’s Board of Directors (the “Board”), and\nNatalia L. Butterworth, Director, Corporate Secretarial and Governance\nat ARO Consulting Inc., has been appointed Corporate Secretary of the\nCompany.\n\n\n \n\n\nMr. Stadnyk brings more than 15 years of experience\nacross biotechnology, capital markets, and public company leadership,\nincluding serving as Head of Life Sciences at the TSX and TSXV, where\nhe advised biotech issuers, boards and institutional investors on\npublic listings, capital formation and strategic positioning, with\ndeep experience in public market execution. Over the course of his\ncareer, he has led and supported over $100 million in institutional\nfinancings, contributed to strategic transactions including the $435\nmillion acquisition of The Supreme Cannabis Company by Canopy Growth,\nand advised public companies across the biotech, healthcare and AI\nsectors. \n\n\n \n\n\nMs. Butterworth is a seasoned corporate governance\nprofessional with over 15 years of experience supporting public and\nprivate companies in governance and regulatory compliance across\nmultiple jurisdictions, spanning the pharmaceutical, technology, and\nfinance sectors. Based in British Columbia, both appointees strengthen\nHelix’s Canadian capital markets and governance expertise as the\nCompany advances its capital markets strategy, including preparations\nfor a planned Nasdaq listing through the Multijurisdictional\nDisclosure System (“MJDS”).\n\n\n \n\n\n“As Helix continues to execute on its corporate and\nclinical development objectives, strengthening our capital markets a...